![]() ![]() It also adds to a run of acquisitions that has already seen Amgen strike deals this year worth a total of $2.2bn in the form of its purchases of Turkish pharma company Mustafa Nevzat, German biotech Micromet and US biopharma Kai Pharmaceuticals. Other executives include Daniel Gudbjartsson, VP Applied Statistics Gsli Msson, VP Informatics and 2 others. The all-cash deal does not require regulatory approval, and is expected to close before the end of 2012. ![]() "We believe Amgen's focus and ability to incorporate our genetic research into their research and development efforts will translate our discoveries into meaningful therapies for patients." Kari Stefansson, founder and CEO at deCODE Genetics, said: "One of the ways to truly realise the full value of human genetics, is to make our research synergistic with drug development efforts where target discovery, validation and prioritisation efforts can be accelerated. Most recently deCode's work saw it identify a gene variant that conferred a high risk for common, late-onset form of Alzheimer's disease. psychology, psychiatry, dentistry, genetics, diseases and Jan 28. Their input allowed deCode to continue its genome sequencing and genotyping research and last year the company struck a research deal with Pfizer to search for variants in the human genome that increase the risk of systemic lupus erythematosis. called Systemedic who has helped me decode numerous medical bills for my stories. Kari Stefansson, the CEO and founder of DeCode, calls scouring databases in this fashion for protective genes a new way of creating drugs that isn’t based on a beautiful hypothesis or lucky. Struggling to find a successful business model the company filed for bankruptcy in the US in 2009 and was acquired by a consortium of venture capitalists. This fits perfectly with our objective to pursue rapid development of relevant molecules that reach the right disease targets while avoiding investments in programmes based on less well-validated targets."ĭeCode's early promise was that it would be able to establish an Iceland-wide genetic database, giving it access to an unrivaled population dataset, but this plan ultimately ran into difficulties with the country's authorities. "This capability will enhance our efforts to identify and validate human disease targets. Robert Bradway, Amgen's president and CEO, said: "deCODE Genetics has built a world-class capability in the study of the genetics of human disease. deCODE Genetics - Provider of a bioinformatics platform for genetic analysis. He was the recipient of the Jakobus Award 2007, The World Glaucoma Association Award for present scientific impact 2007, The European Society of Human Genetics Award 2009, The Andre Jahre Award 2009, and The Sir Hans Krebs Medal 2016.Amgen has acquired deCode Genetics, paying $415m for the Reykjavik-based genetic information firm in a deal it says will boost its ability to identify and validate disease targets.ĭeCode was founded in 1996 to capitalise on genomic research and it has since discovered genetic risk factors for dozens of diseases ranging from cardiovascular disease to cancer. Stefánsson was chosen by Time magazine as one of the 100 most influential men of the year for 2007 and by Newsweek as one of the 10 most important biologists of the 21 century. ![]() He has published numerous articles on the genetics of common/complex diseases and has been among the leaders of the world in the discovery of variants in the sequence of the human genome that associate with the risk of common/complex traits. We at deCODE genetics sequenced the viral genomes from everybody with a documented Covid-19 in Iceland. from the University of Iceland and is board-certified in neurology and neuropathology in the United States. Geneticist Founder and CEO of deCODE genetics A student of human diversity. From 1983 to 1993, he held faculty positions in Neurology, Neuropathology and Neurosciences at the University of Chicago. Stefánsson was a professor of Neurology, Neuropathology and Neuroscience at Harvard University. In Iceland he has pioneered the use of population-scale genetics to understand variation in the sequence of the human genome. Stefánsson was appointed the Chairman of the Board of Directors of deCODE genetics in December 1999. Kári Stefánsson a (or Kari Stefansson born 6 April 1949) 1 is an Icelandic neurologist and founder and CEO of Reykjavik-based biopharmaceutical company deCODE genetics. has served as President, Chief Executive Officer and a Director since he founded deCODE genetics in August 1996. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |